Abstract
Edaravone is a low molecular weight antioxidant that scavenges free radicals and inhibits lipid peroxidation, thereby reducing oxidative damage to brain cells and other organs. Edaravone is mainly known as an effective agent in the treatment of ischemic stroke and amyotrophic lateral sclerosis. The aim: to investigate the possibilities of edaravone in its use in the treatment of patients with diabetes. Materials and methods. To solve the task, a search and analysis of full-text articles was conducted in the PubMed, Web of Science, Google Scholar, and Scopus databases. The search was conducted using the key term «edaravone» and «diabetes mellitus» included English-language and Ukrainian-language publications over the past 20 years (from April 2003 to July 2023). Results. A total of 112 publications were identified and analyzed. It was established that edaravone improves the clinical course and can be useful in the treatment and prevention of diabetes and its complications (diabetic neuropathy, retinopathy, nephropathy, cardiomyopathy, etc.). This dictates the need for further clinical studies to study the possibilities of including edaravone in programs for the treatment and prevention of diabetes and its complications.
Publisher
Ukrainian Diabetology Association